Shares of Moderna ( MRNA) rose 177% in Wednesday trading, while Merck’s ( MRK) rose some 12%, after the pharma companies announced positive results from a late-stage trial of an experimental ...

Moderna (MRNA) is set for three data readouts on its individualized neoantigen therapies, or INT, in the near term, serving as potential stock catalysts for the company, UBS Secur ...

Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company one of the top performers in the S&P 500. Investors responded positively to new pipeline updates, encouraging ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, ...

What Happened? A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic ...